Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

30.09 +0.40 (+1.36%)
Streaming Delayed Price Updated: 1:51 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Companies That Grow Through Acquisitions: Pros And Cons
We hit one of dividend growth investors’ favorite business model types: growth through acquisitions. While it often rhymes with dividend growth, there are pros and cons to consider. 
Via Talk Markets
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
Via Benzinga
3 Top-Rated Value Stocks That Analysts Are Loving Now
Stuff your stockings with these top-rated value stocks. Analysts are feeling good about this value stocks heading into 2024. 
Via InvestorPlace
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Is Pfizer Stock a Buy Now?
The company keeps falling out of favor with the market. 
Via The Motley Fool
Uncovering Dividend Opportunities with NYSE:PFE.
Balancing Dividends and Fundamentals: The Case of PFIZER INC (NYSE:PFE). 
Via Chartmill
New Partnership Between Generis And Risetime Provides Easy and Compliant Information Management for Cosmetics Industry
CHICAGO - Nov. 29, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the... 
Via PRLog
Exposures Product Safety
How Is The Market Feeling About Pfizer?
Via Benzinga
Why Biodexa Pharmaceuticals Stock (BDRX) Is Skyrocketing
Biodexa Pharmaceuticals PLC-ADR (NASDAQ: BDRX) shares are trading higher by 60% to $4.48 Monday morning after the company announced it has acquired the rights to tolimidone, an experimental drug... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares. 
Via The Motley Fool
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
Global Heart Failure Drugs Market Breakdown by Application (Reduced Ejection Fraction, Preserved Ejection Fraction) by Type (ACE inhibitors, Beta Blockers, Diuretics, Sacubitril Valsartan, Others) by... 
Via SBWire
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
Behind the Scenes of Pfizer's Latest Options Trends
Via Benzinga
18 Analysts Have This to Say About Pfizer
Via Benzinga
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO. 
Via Investor's Business Daily
2 Stocks You'll Be Grateful You Bought at These Bargain Prices
These companies are leaders in their industries. 
Via The Motley Fool
Why Is COVID-19 Vaccine Maker Moderna Stock Trading Lower Today?
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc (NYSE: PFE) /  
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Safeguard your portfolio with these three bargain stocks
Nobody is sure about the market's direction today; these are the stocks that can offer you a good chunk of growth at very little downside risk 
Via MarketBeat
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Investors have favored an exciting billion-dollar opportunity at Eli Lilly. 
Via The Motley Fool
Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth
Although you can’t usually have your cake and eat it too, these compelling high-yield dividend growth stocks may prove otherwise. 
Via InvestorPlace
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
Exposures Product Safety
The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023
Here are just a few of the most undervalued sleeper stocks investors may want to consider heading into the new year. 
Via InvestorPlace
What's Going On With Penny Stock AgeX Therapeutics?
Serina Therapeutics Inc, a privately held, clinical-stage biotechnology company, entered into a License Agreement under which Pfizer Inc (NYSE: PFE) will license, on a non-exclusive basis, Serina's  
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.